News

The YUKAWA-2 (StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced Cardiovascular Risk) trial met its co-primary endpoints: the percent reduction from baseline

BTG and SciClone previously entered into an agreement granting SciClone exclusive licensing and distribution rights to DC Bead in China. Under the agreement, SciClone will purchase product from

The clinical test are being conducted through Immunotech Laboratories, BG ("IMMB-BG") a 49% owned subsidiary of Immunotech Laboratories. Since 2013, IMMB-BG hired and funded the Clinical Research Organization

The first newly allowed patent application (serial No: 05723389.2) entitled "Systems and Methods for Clonal Expression in Plants," includes claims to a system for generating transgenic hairy root

Elelyso can now be used as a long-term enzyme replacement therapy (ERT) for the treatment of these patients. Pfizer Global Innovative Pharma Business senior vice-president of Global Medical

Following the transaction, Patheon’s biologic drug substance business, a unit of DPx Holdings, will span four facilities in Europe, Australia and North America and include 550 employees globally.

The product, which is used to increase female sexual arousal and desire and satisfaction, is approved for marketing in alternative markets which excludes all medical and mainstream sales

The company has already completed the pre-launch preparation of the generic drug and will now be entitled to 180 days of marketing exclusivity under Hatch Waxman rules. According

Currently, PF-06425090 is in Phase II clinical development and it is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. FDA fast track